AR105552A1 - Un análogo específico de trifluoroetilquinolina para usar en el tratamiento de síndrome de sjögren - Google Patents

Un análogo específico de trifluoroetilquinolina para usar en el tratamiento de síndrome de sjögren

Info

Publication number
AR105552A1
AR105552A1 ARP160101079A ARP160101079A AR105552A1 AR 105552 A1 AR105552 A1 AR 105552A1 AR P160101079 A ARP160101079 A AR P160101079A AR P160101079 A ARP160101079 A AR P160101079A AR 105552 A1 AR105552 A1 AR 105552A1
Authority
AR
Argentina
Prior art keywords
trifluoroethylquinoline
specific analog
syndrome treatment
sjögren syndrome
sjögren
Prior art date
Application number
ARP160101079A
Other languages
English (en)
Inventor
Nayar Saba
Anthony Fahy William
Barone Francesca
Anthony Allen Rodger
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of AR105552A1 publication Critical patent/AR105552A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La N-{(R)-1-[8-cloro-2-(1-oxipiridin-3-il)-quinolin-3-il]-2,2,2-trifluoroetil pirido-[3,2-d]pirimidin-4-ilamina es efectiva en el tratamiento y/o la prevención de síndrome de Sjögren.
ARP160101079A 2015-04-21 2016-04-20 Un análogo específico de trifluoroetilquinolina para usar en el tratamiento de síndrome de sjögren AR105552A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use

Publications (1)

Publication Number Publication Date
AR105552A1 true AR105552A1 (es) 2017-10-18

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101079A AR105552A1 (es) 2015-04-21 2016-04-20 Un análogo específico de trifluoroetilquinolina para usar en el tratamiento de síndrome de sjögren

Country Status (27)

Country Link
US (1) US10493074B2 (es)
EP (1) EP3285772B1 (es)
JP (1) JP6721606B2 (es)
KR (1) KR102627370B1 (es)
CN (1) CN107530344B (es)
AR (1) AR105552A1 (es)
AU (1) AU2016251236B2 (es)
BR (1) BR112017020591B8 (es)
CA (1) CA2981631C (es)
CL (1) CL2017002669A1 (es)
CO (1) CO2017010573A2 (es)
CY (1) CY1122572T1 (es)
DK (1) DK3285772T3 (es)
EA (1) EA032432B1 (es)
ES (1) ES2763335T3 (es)
GB (1) GB201506786D0 (es)
HR (1) HRP20192273T1 (es)
HU (1) HUE047162T2 (es)
IL (1) IL254766B (es)
LT (1) LT3285772T (es)
MX (1) MX2017013148A (es)
MY (1) MY192972A (es)
PL (1) PL3285772T3 (es)
PT (1) PT3285772T (es)
SG (1) SG11201707789YA (es)
SI (1) SI3285772T1 (es)
WO (1) WO2016170014A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1761540B1 (en) * 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
RS54706B1 (en) * 2007-03-23 2016-08-31 Amgen Inc. HETEROCYCLIC UNITS AND THEIR USES
MY173795A (en) * 2009-11-05 2020-02-24 Incozen Therapeutics Pvt Ltd Novel benzopyran kinase modulators
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
PL3008053T3 (pl) * 2013-06-14 2018-08-31 Gilead Calistoga Llc Inhibitory 3-kinazy fosfatydyloinozytolu

Also Published As

Publication number Publication date
JP2018513862A (ja) 2018-05-31
CY1122572T1 (el) 2021-01-27
HRP20192273T1 (hr) 2020-03-06
ES2763335T3 (es) 2020-05-28
PL3285772T3 (pl) 2020-05-18
CO2017010573A2 (es) 2018-03-09
US10493074B2 (en) 2019-12-03
CA2981631C (en) 2023-02-21
CL2017002669A1 (es) 2018-05-11
AU2016251236B2 (en) 2018-06-14
HUE047162T2 (hu) 2020-04-28
EP3285772A1 (en) 2018-02-28
PT3285772T (pt) 2020-01-14
AU2016251236A1 (en) 2017-11-09
LT3285772T (lt) 2020-01-10
IL254766A0 (en) 2017-12-31
DK3285772T3 (da) 2020-01-13
BR112017020591B1 (pt) 2023-02-07
CN107530344B (zh) 2020-03-17
EA201792318A1 (ru) 2018-05-31
SI3285772T1 (sl) 2020-02-28
GB201506786D0 (en) 2015-06-03
KR102627370B1 (ko) 2024-01-18
IL254766B (en) 2020-05-31
MX2017013148A (es) 2018-02-21
BR112017020591A2 (pt) 2018-07-03
US20180092921A1 (en) 2018-04-05
JP6721606B2 (ja) 2020-07-15
BR112017020591B8 (pt) 2023-05-16
WO2016170014A1 (en) 2016-10-27
KR20170140245A (ko) 2017-12-20
SG11201707789YA (en) 2017-11-29
CA2981631A1 (en) 2016-10-27
EP3285772B1 (en) 2019-10-02
EA032432B1 (ru) 2019-05-31
CN107530344A (zh) 2018-01-02
MY192972A (en) 2022-09-20

Similar Documents

Publication Publication Date Title
IL288231A (en) An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
IL251285B (en) 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of virus infection
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2018013559A2 (es) Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds)
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2017000394A (es) Vacunas para virus influenza y usos de las mismas.
CL2016002422A1 (es) Cromeno y 1, 1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasas.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
EP4342545A3 (en) Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
AR094873A1 (es) Métodos y composiciones para detectar y tratar mutantes de akt resistentes a fármacos
EP3533451A4 (en) APPLICATION OF PAEENIFLORIN-6'-O-BENZENE SULFONATE IN MEDICINE FOR THE TREATMENT OF SJÖGREN SYNDROME
GB201700692D0 (en) Novel compounds and their use in the treatment of schistosomiasis
AR105552A1 (es) Un análogo específico de trifluoroetilquinolina para usar en el tratamiento de síndrome de sjögren
ES2660372T8 (es) Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases